Cytokinetics, Inc. (CYTK)
| Market Cap | 1.74B |
| Revenue (ttm) | 58.55M |
| Net Income (ttm) | -134.99M |
| Shares Out | 71.20M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $24.84 |
| Previous Close | $24.32 |
| Change ($) | 0.52 |
| Change (%) | 2.14% |
| Day's Open | 24.42 |
| Day's Range | 24.21 - 24.96 |
| Day's Volume | 266,528 |
| 52-Week Range | 14.71 - 30.14 |
Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.86% and -16.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an o...
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021 at...
Next Cohort to Enroll Patients on Background Therapy of Disopyramide Next Cohort to Enroll Patients on Background Therapy of Disopyramide
SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2021 it granted stock options to purchase an aggregate of 69,800...
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associa...
SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM E...
Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposur...
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to part...
SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discover...
Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pres...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 26, 2021 it granted stock options to purchase an aggregate of 9,...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it is joining the European Organisation for Rare Diseases (EU...
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF
Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development Appointment Adds to Board Expertise in Commercial Development and Ma...
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:0...
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 29, 2021 it granted stock options to purchase an aggregate of 13,...
Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designat...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to parti...
Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regulatory Inte...
Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support Rationale...
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left V...
Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking ...
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62...
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting
In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future .
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to partic...
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparation s for Regulatory Interaction s Following Positive Results of GALACTIC-HF
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Amazon and Yelp.
Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization Appointment Strengthens Commercial, Market Access and Spec...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records rela...
New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction New Findings from Studies of Cardiac Myosin Inhi...
Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 30, 2020 it granted stock options to purchase an aggregate of 2,8...
Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session
Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q3 2020 Results - Earnings Call Transcript
Cytokinetics (CYTK) delivered earnings and revenue surprises of 91.53% and 997.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2020 at 4:00 ...
Amgen Inc. (NASDAQ:AMGN) and its partner, Cytokinetics Inc. (NASDAQ:CYTK), took a punch to the gut last week when the heart drug they were collaborating on failed to meet expectations. Thousand Oaks, Ca...
Amgen and Cytokinetics disappointed with key Phase 3, final-stage trial results for a heart treatment that aims to reduce cardiovascular death; sending CYTK crashing and AMGN down hard. The post Amgen, ...
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, wh... [Read more...]
| Industry Biotechnology | IPO Date Apr 29, 2004 |
| CEO Robert Blum | Employees 184 |
| Stock Exchange NASDAQ | Ticker Symbol CYTK |
Financial Performance
In 2020, Cytokinetics's revenue was $55.83 million, an increase of 107.79% compared to the previous year's $26.87 million. Losses were -$127.29 million, 4.60% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for Cytokinetics stock is "Buy." The 12-month stock price forecast is 32.64, which is an increase of 31.40% from the latest price.